Industry insists Australian clinical trials are internationally cost competitive contrary to 2012 report

 

SYDNEY, May 20, 2013 /PRNewswire/ -- Industry claims that a report of Australian clinical trial costs is flawed. The report (https://www.kpmg.com/Global/en/IssuesAndInsights/ArticlesPublications/Documents/competitive-alternatives-special-report.pdf) on the global competitiveness of 14 countries came out this time last year, ranking Australia as the second most expensive country to run clinical trials, subsequent press accepted the report and said what a shame it was that Australia was so costly compared with other countries...

In the spirit of promoting Australia's advantages, timely for International Clinical Trials Day (20th May 2013), Australian R&D industry representatives are now making noise in response to the report. The report rankings were based on areas such as labour costs, transport, facility lease costs and utilities such as electricity. Exact data sources are unclear.

"The report should be judged in context with the data it used" says Luke Edington, Clinical Project Management (http://www.datapharmaustralia.com/about-us/our-leaders) at Datapharm Australia. "Broad economic indicators are not sufficient to draw solid conclusions on clinical trial management costs, and it is unfair to rank a country's R&D costs on these factors alone. It seems no consideration was given to R&D Tax incentive(s), regulatory environments, time to first patient, patient population access, Investigator fees & laboratory costs, recruitment rates, insurance, ethics fees, CRO operating costs and other quality dynamics." says Mr Edington

If you consider that the Australian R&D tax incentive was not included in this report, currently being up to 45%, this alone would have placed Australia competitively with Russia. "Foreign entities can claim R&D Tax incentives (http://www.swansonreed.com.au/product/45-rebate-for-australian-rd-costs/) through their Australian subsidiaries at 45 cents in the dollar, that means $450,000 for $1,000,000 foreign spend in Australia", says Adam Rogers, R&D Tax specialist at Swanson & Reed.

The message to industry, industry groups, reporters and decision makers in the field is to examine the data in detail before placing too much importance on the conclusions.

For media enquiries contact [email protected]

SOURCE Research Receptor

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.